scPharmaceuticals (SCPH)
(Delayed Data from NSDQ)
$4.57 USD
+0.08 (1.78%)
Updated Apr 29, 2024 03:59 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
SCPH 4.57 +0.08(1.78%)
Will SCPH be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for SCPH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SCPH
ScPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Tops Revenue Estimates
scPharmaceuticals, Inc. (SCPH) Loses -21.78% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
SCPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue Estimates
Recent Price Trend in scPharmaceuticals, Inc. (SCPH) is Your Friend, Here's Why
scPharmaceuticals, Inc. (SCPH) Is a Great Choice for 'Trend' Investors, Here's Why
Other News for SCPH
Craig-Hallum Remains a Buy on scPharmaceuticals (SCPH)
scPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg/mL) Injection
scPharmaceuticals announces first patient enrolled in study of SCP-111
12 Health Care Stocks Moving In Friday's Pre-Market Session
Analysts Are Bullish on These Healthcare Stocks: Immuneering (IMRX), Structure Therapeutics, Inc. Sponsored ADR (GPCR)